Area de Medicina i Cirurgia Animal

Cerdanyola del Vallès, Spain

Area de Medicina i Cirurgia Animal

Cerdanyola del Vallès, Spain
SEARCH FILTERS
Time filter
Source Type

Fonseca C.,Area de Medicina i Cirurgia Animal | Caminal M.,XCELIA | Peris D.,Grup dEnginyeria Cel Lular i Tissular | Barrachina J.,Hospital ASEPEYO Sant Cugat | And 6 more authors.
Cytotechnology | Year: 2014

Osteochondral injuries are common in humans and are relatively difficult to manage with current treatment options. The combination of novel biomaterials and expanded progenitor or stem cells provides a source of therapeutic and immunologically compatible medicines that can be used in regenerative medicine. However, such new medicinal products need to be tested in translational animal models using the intended route of administration in humans and the intended delivery device. In this study, we evaluated the feasibility of an arthroscopic approach for the implantation of biocompatible copolymeric poly-d,l-lactide-co- glycolide (PLGA) scaffolds in an ovine preclinical model of knee osteochondral defects. Moreover this procedure was further tested using ex vivo expanded autologous chondrocytes derived from cartilaginous tissue, which were loaded in PLGA scaffolds and their potential to generate hyaline cartilage was evaluated. All scaffolds were successfully implanted arthroscopically and the clinical evolution of the animals was followed by non invasive MRI techniques, similar to the standard in human clinical practice. No clinical complications occurred after the transplantation procedures in any of the animals. Interestingly, the macroscopic evaluation demonstrated significant improvement after treatment with scaffolds loaded with cells compared to untreated controls. © 2013 Springer Science+Business Media Dordrecht.


Caminal M.,Banc de Sang i Teixits | Moll X.,Area de Medicina i Cirurgia Animal | Codina D.,Hospital ASEPEYO | Rabanal R.M.,Area de Medicina i Cirurgia Animal | And 5 more authors.
Biotechnology Letters | Year: 2014

Clinical translation of emerging technologies aiming at cartilage resurfacing is hindered by neither the appropriate scaffold design nor the optimal cell source having been defined. Here, critical-sized, chondral-only focal defects were created in sheep and treated with clinical-grade, co-polymeric poly-lactide:polyglycolic acid scaffolds either alone or seeded with 3.3 × 106 ± 0.4 × 106 autologous bone marrow-derived mesenchymal stromal cells and studied over 12 month follow-up. An untreated group was included for comparison. Second-look arthroscopy performed at 4 months post-treatment evidenced the generation of neocartilage of better quality in those defects treated with cells. However, macroscopic scores in the cell-treated group declined significantly from 7.5 ± 2.3 at 4 months to 3.1 ± 2.6 (p = 0.0098) at 12 months post-treatment, whereas the other two experimental groups remained unaltered during 4-12 month post-treatment. The effectiveness of the cell-based approach proposed in this study is thus restricted to between months 1 and 4 post-treatment. © 2014 Springer Science+Business Media Dordrecht.

Loading Area de Medicina i Cirurgia Animal collaborators
Loading Area de Medicina i Cirurgia Animal collaborators